Joseph P. Zackular
Joseph P. Zackular, Ph.D.
Assistant Professor of Pathology and Laboratory Medicine
Member, Center for Molecular Studies in Digestive and Liver Diseases
Member, Penn Institute for RNA Innovation
Member, PennCHOP Microbiome Program
Department: Pathology and Laboratory Medicine
Contact information
1211A Abramson Research Center
3615 Civic Center Blvd
Philadelphia, PA 19104
3615 Civic Center Blvd
Philadelphia, PA 19104
Office: 2674265016
Email:
zackular@upenn.edu
zackular@upenn.edu
Graduate Group Affiliations
Publications
Education:
B.S. (Microbiology)
University of Massachusetts - Amherst, 2008.
M.S. (Microbiology)
University of Massachusetts - Amherst, 2009.
Ph.D. (Microbiology & Immunology)
University of Michigan, 2014.
Permanent linkB.S. (Microbiology)
University of Massachusetts - Amherst, 2008.
M.S. (Microbiology)
University of Massachusetts - Amherst, 2009.
Ph.D. (Microbiology & Immunology)
University of Michigan, 2014.
Description of Research Expertise
The Zackular laboratory is focused on understanding how interactions between the host, gut microbiota, and pathogens impact human health and disease. The labs efforts primarily center on the nosocomial pathogen, Clostridioides difficile, which is an urgent global public health threat. The Zackular lab is interested in understanding how the gut microbiota shapes C. difficile fitness and virulence, and the team is studying how this complex microbial community alters host responses to infection. Recent work from the Zackular lab has focused on elucidating cooperative interactions between C. difficile and other pathogens, such as the enterococci. Leveraging knowledge learned from studying polymicrobial interactions and microbial ecology during infection, the Zackular lab is also developing novel vaccine strategies for the prevention of C. difficile infection and using microbiome-based therapies for the treatment of disease.Dr. Zackular is co-director of the Center for Microbial Medicine at the Children’s Hospital of Philadelphia, which focuses on i.) bringing microbiome-based medicine to pediatric patients and ii) using whole genome sequencing of pathogens to provide children with improved and personalized treatments for infections.
Selected Publications
Soto Ocaña, J., Friedman E.S., Keenan, O., Bayard, N.U., Ford E., Tanes C., Munneke M.J., Beavers W.N., Skaar E.P., Bittinger K., Zemel B.S., Wu G.D.†, Zackular J.P. : Metal availability shapes early life microbial ecology and community succession. mBio 15(11): e0153424, October 2024.Alameh M., Semon, A., Bayard N.U., Pan Y., Knox J., Dwivedi G., Glover R.C., Rangel P.C., Tanes C., Bittinger K., She Q., Maslanka J.R., Planet P.J., Moustafa A.M., Davis B., Chevrier A., Beattie M., Ni H., Blizard G., Furth E.E., Mach R H., Lavertu M., Sellmyer M., Tam Y., Abt M.C., Weissman D., Zackular J.P. : A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection. Science 386(6717): 69-75, October 2024 Notes: doi: 10.1126/science.adn4955.
Smith A.B., Specker J.T., Hewlett K.K., Scoggins T.R., Knight M., Lustig A.M., Lid Y., Evans K.M., Guob Y., She Q., Christopher M.W., Garrett T.J., Moustafa A.M., Van Tyne D., Prentice B.M., Zackular J.P.: Liberation of host heme by Clostridioides difficile-mediated damage enhances Enterococcus faecalis fitness during infection. mBio 15(1): e0165623, January 2024.
Soto Ocaña J., Bayard N.U., Hart J.L., Thomas A., Furth E.E., Lacy D.B., Aronoff D.M., Zackular J.P. : Nonsteroidal anti-inflammatory drugs sensitize epithelial cells to Clostridioides difficile toxin-mediated mitochondrial damage. Science Advances 9(29): eadh5552, July 2023.
Smith A.B., Jenior M.L., Keenan O., Hart J.L., Specker J, Abbas A, Rangel P.C., Di C., Green J., Bustin K. A., Gaddy J.A., Nicholson M.R., Laut C., Kelly B.J., Matthews M.L, Evans D.L., Van Tyne D., Furth E.E., Papin J.A., Bushman F.D., Erlichman J., Baldassano R.N., Silverman M.A., Dunny G.M., Prentice B.M., Skaar E.P., and Zackular J.P. : Enterococci enhance Clostridioides difficile pathogenesis. Nature 611(7937): 780-786, Nov 2022.
Bushman FD, Conrad M, Ren Y, Zhao C, Gu C, Petucci C, Kim MS, Abbas A, Downes KJ, Devas N, Mattei LM, Breton J, Kelsen J, Marakos S, Galgano A, Kachelries K, Erlichman J, Hart JL, Moraskie M, Kim D, Zhang H, Hofstaedter CE, Wu GD, Lewis JD, Zackular JP, Li H, Bittinger K, Baldassano R.: Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease. Cell Host & Microbe 28: 422-433, Sep 2020.
Abbas A. and Zackular J.P. : Microbe-microbe Interactions During Clostridioides difficile Infection. Current Opinions in Microbiology 53: 19–25, February 2020.
Smith A.B., Soto Ocana J., and Zackular J.P.: From Nursery to Nursing House: Emerging Concepts in Clostridioides difficile Pathogenesis. Infection and Immunity 88(7): e00934-19, June 2020.
Zackular J.P., Kirk Leslie, Trindade B.C., Skaar E.P., and Aronoff D.M.: Misoprostol protects mice against severe Clostridium difficile infection and promotes recovery of the gut microbiota after antibiotic perturbation. Anaerobe 58: 89-94, June 2019.
Zackular J.P., Moore J.L., Jordan A.T., Juttukonda L.J., Noto M.J., Nicholson M.R., Crews J.D., Semler M.W., Zhang Y., Ware L.B., Washington M.K., Chazin W.J., Caprioli R.M., Skaar E.P.: Dietary Zinc Alters the Microbiota and Decreases Resistance to Clostridium Difficile Infection Nature Medicine 22(11): 1330-34, 2016.